Sphera Funds Management LTD. purchased a new position in shares of argenx SE – (NASDAQ:ARGX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 136,381 shares of the company’s stock, valued at approximately $10,343,000. argenx accounts for approximately 1.2% of Sphera Funds Management LTD.’s investment portfolio, making the stock its 18th biggest position. Sphera Funds Management LTD. owned about 0.42% of argenx at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ARGX. Redmile Group LLC grew its stake in shares of argenx by 182.2% during the 2nd quarter. Redmile Group LLC now owns 673,300 shares of the company’s stock worth $55,790,000 after purchasing an additional 434,700 shares during the period. FMR LLC grew its stake in shares of argenx by 12.3% during the 3rd quarter. FMR LLC now owns 3,475,049 shares of the company’s stock worth $263,548,000 after purchasing an additional 380,661 shares during the period. BB Biotech AG grew its stake in shares of argenx by 63.6% during the 3rd quarter. BB Biotech AG now owns 734,739 shares of the company’s stock worth $55,723,000 after purchasing an additional 285,690 shares during the period. Jennison Associates LLC grew its stake in shares of argenx by 54.0% during the 3rd quarter. Jennison Associates LLC now owns 511,221 shares of the company’s stock worth $38,771,000 after purchasing an additional 179,208 shares during the period. Finally, Laurion Capital Management LP acquired a new position in shares of argenx during the 3rd quarter worth $10,693,000. 64.40% of the stock is currently owned by institutional investors and hedge funds.

Shares of argenx stock traded down $0.83 on Friday, hitting $102.77. The company’s stock had a trading volume of 21,877 shares, compared to its average volume of 259,440. argenx SE – has a 52-week low of $29.33 and a 52-week high of $111.43. The firm has a market capitalization of $3.40 billion, a PE ratio of -73.41 and a beta of 1.67.

A number of equities analysts have recently weighed in on the stock. Wedbush upped their price target on shares of argenx from $114.00 to $121.00 and gave the stock a “positive” rating in a research note on Tuesday, September 18th. Evercore ISI assumed coverage on shares of argenx in a research report on Monday, October 15th. They issued an “outperform” rating and a $110.00 price objective on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $154.00 price objective on shares of argenx in a research report on Monday, September 17th. SunTrust Banks boosted their price objective on shares of argenx to $132.00 and gave the stock an “in-line” rating in a research report on Tuesday, September 18th. Finally, JMP Securities boosted their price objective on shares of argenx to $150.00 and gave the stock an “outperform” rating in a research report on Monday, September 17th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $136.00.

TRADEMARK VIOLATION WARNING: “Sphera Funds Management LTD. Purchases Shares of 136,381 argenx SE – (ARGX)” was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/sphera-funds-management-ltd-purchases-shares-of-136381-argenx-se-argx/2668565.html.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Article: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.